By FieldPulse Staff · March 17, 2026
Tags: strategy, leadership
Senate investigation finds GSK avoided $367.6M in Medicaid rebates by discontinuing Flovent and replacing it with an authorized generic. Asthma hospitalizations rose 17.5% in three months after discontinuation.
Senator Maggie Hassan released a Senate Health Committee investigation report on March 17, 2026 finding that GlaxoSmithKline deliberately discontinued its Flovent inhaler and replaced it with an "authorized generic" version at prices that sidestepped approximately $367.6 million in Medicaid rebates in 2024 alone. The report found that following Flovent's discontinuation, patients experienced a 17.5% increase in asthma-related hospitalizations in the three months after the drug was pulled from the market. Hassan called the maneuver "egregious" and said GSK had "gamed the system" by exploiting a